UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease: London, UK Monday, December 15, 2025, 16:00 Hrs [IST] GSK plc announced that ...

London: GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

No significant differences in the safety or effectiveness of tralokinumab were observed by racial subgroup among patients with AD.

GSK (GSK) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting ...

邱爷爷：“李药师，我现在服用的治疗痛风的药物控制痛风效果不太好，听说现在有一款治疗痛风的新药上市了啊？您能不能给我介绍一下这个药物。” ...

The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively ...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced Sailaja Battula, PhD has been appointed as the ...

Profs Carl Philpott and Claire Hopkins discuss how the MACRO trial challenges long-held assumptions about chronic ...